Several Aeromonas species, including Aeromonas hydrophila, have been known to produce CphA, a chromosomal metallo β-lactamase (MBL). We aimed to evaluate the clinical usefulness of modified carbapenem inactivation method (mCIM) in conjunction with EDTA (eCIM) or sodium mercaptoacetate (SMA-mCIM) for MBL-producing Aeromonas species. Fifty-six clinical isolates of Aeromonas species stored at the University of the Ryukyus Hospital were used in this study. The antimicrobial susceptibility testing was performed using a VITEK®2 AST-N404 card (bioMerieux, Marcy-l'Etoile, France) and the results were interpreted according to the CLSI guideline M45 3rd edition. The carbapenemase genes, namely blaGES, blaIMP, blaKPC, blaNDM, blaOXA-48-like, blaVIM, and blaCphA, were detected by PCR. The production of carbapenemase was evaluated using the mCIM and the differentiation of MBL was eCIM and SMA-mCIM. The resistance rates to imipenem and meropenem were 21.4 % (12/56) and 32.1 % (18/56), respectively. The mCIM showed a sensitivity of 100 % (33/33 blaCphA positive isolates) and a specificity of 95.7 % (22/23 blaCphA negative isolates) for the tested isolates. Among the 33 mCIM-positive isolates, 29 (87.9 %) for eCIM, and 6 (18.2 %) for SMA-mCIM were judged as MBL positive, respectively. It is suggested that the mCIM in conjunction with EDTA is useful for detecting MBL production in Aeromonas species harboring blaCphA.